Baseline characteristics of the pooled MORGAM cohort (n=66 951)
| Characteristics | Median (IQR) or n (%) | Missing values |
| Age (years) | 53.5 (46.4–61.2) | 0 (0.0%) |
| Sex (n (%) men) | 32 855 (49.1) | 0 (0.0%) |
| BMI (kg/m2) | 26.4 (23.9 to 29.5) | 480 (0.7%) |
| Systolic blood pressure (mm Hg)* | 137 (124 to 152) | 459 (0.7%) |
| Total serum cholesterol (mmol/L) | 5.9 (5.2 to 6.8) | 669 (1.0%) |
| Daily smoker | 17 305 (26.0) | 370 (0.6%) |
| History of diabetes | 3526 (5.3) | 83 (0.1%) |
| Taking antihypertensive drugs | 11 977 (19.2) | 4576 (6.8%) |
| Hypertension† | 33 470 (52.2) | 2781 (4.2%) |
| Average daily alcohol consumption (g) | 3.0 (0.0 to 12.0) | 11 777 (17.6%) |
| History of MI or stroke | 3625 (5.4) | 62 (0.1%) |
| C reactive protein (mg/L) | 1.4 (0.7 to 2.9) | 34 058 (50.9%)‡ |
| Nt-proBNP (pg/mL) | 52 (27 to 96) | 40 903 (61.1%)§ |
| log10 (Nt-proBNP (pg/mL)) | 1.7 (1.4 to 2.0) | 40 903 (61.1%)§ |
| Creatinine (mg/dL) | 0.8 (0.7 to 0.9) | 34 065 (50.9%)¶ |
| eGFR¶ | 94.8 (84.0 to 103.5) | 34 065 (50.9%)‡ |
*Mean of two measurements.
†Systolic blood pressure ≥140 mm Hg and/or taking antihypertensive drugs.
‡Missing by design in the Tromsø Study and partly in other studies than the 1997 cohort of FINRISK (online supplemental tables S2 and S4).
§Missing by design in DAN-MONICA and the Tromsø Study, and partly in other studies except the 1997 cohort of FINRISK (online supplemental tables S1, S2 and S4).
¶Using the Chronic Kidney Disease Epidemiology Collaboration formula with creatinine.
BMI, body mass index; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; MORGAM, MOnica Risk, Genetics, Archiving and Monograph; Nt-proBN, N-terminal-pro B-type natriuretic peptide.